Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications

- Vulvar and vaginal atrophy (VVA) affects up to about 50% of postmenopausal women.
- Ospemifene is an estrogen receptor agonist/antagonist with tissue-specific effects.
- Ospemifene has beneficial estrogen-like effects on the vaginal epithelium.
- Effects are neutral on endometrium, antiestrogenic on breast, and estrogenic on bone.
- The preclinical findings are consistent with clinical studies for treatment of VVA.